Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBITDA (2023 - 2025)

CG Oncology filings provide 3 years of EBITDA readings, the most recent being -$48.7 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 27.99% to -$48.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$190.8 million, a 66.37% decrease, with the full-year FY2025 number at -$190.8 million, down 66.37% from a year prior.
  • EBITDA hit -$48.7 million in Q4 2025 for CG Oncology, up from -$51.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$9.7 million in Q1 2023 to a low of -$51.1 million in Q3 2025.
  • Median EBITDA over the past 3 years was -$27.1 million (2024), compared with a mean of -$30.1 million.
  • Biggest five-year swings in EBITDA: plummeted 131.14% in 2024 and later fell 27.99% in 2025.
  • CG Oncology's EBITDA stood at -$19.4 million in 2023, then crashed by 96.58% to -$38.0 million in 2024, then fell by 27.99% to -$48.7 million in 2025.
  • The last three reported values for EBITDA were -$48.7 million (Q4 2025), -$51.1 million (Q3 2025), and -$48.7 million (Q2 2025) per Business Quant data.